Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

Hepatology

Volumn 57, Issue 4, 2013, Pages 1333-1342

  Mohd Hanafiah, Khayriyyah ^a   Groeger, Justina ^b   Flaxman, Abraham D ^c   Wiersma, Steven T ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY;

AGE; ARTICLE; ASIA; AUSTRALIA AND NEW ZEALAND; CENTRAL AMERICA; EASTERN EUROPE; EUROPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MIDDLE EAST; NORTH AFRICA; PACIFIC ISLANDS; PRIMARY PREVENTION; PRIORITY JOURNAL; SEROPREVALENCE; SOUTH AND CENTRAL AMERICA; SOUTH ASIA; SOUTHEAST ASIA; SYSTEMATIC REVIEW; WESTERN EUROPE; WESTERN HEMISPHERE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; VIRAL VACCINES; WORLD HEALTH; YOUNG ADULT;

EID: 84876149257     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26141     Document Type: Article

References (35)

1. Global Burden of Disease Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-29.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
3. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-344.
4. Hepatitis C: global prevalence (update). Wkly Epidemiol Rec 1999; 74: 425-427.
5. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
6. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
7. Kim WR, Ward JW, Cheever LW, Dan C, Dee L, Zola J. Transforming the current infrastructure for combating HBV and HCV infections. J Fam Pract 2010; 59( Suppl): S65-S70.
8. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. HEPATOLOGY 2010; 51: 729-733.
9. Peters MG, Weinbaum C, Tan L, Baine WB, Dienstag JL, Liang TJ, et al. Recommendations for prevention, screening, and diagnosis of HBV and HCV infections. J Fam Pract 2010; 59( Suppl): S29-S35.
10. GBD 2005 Study. Global burden of diseases, injuries and risk factors study operations manual (final draft, January 2009). Accessed December 5, 2010 at http://www.globalburden.org
11. Flaxman AD, Vos T, Lim S, Murray CJL (Eds). Integrated Meta-Regression Framework for Descriptive Epidemiology, University of Washington: Seattle, 2013.
12. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28: 6653-6657.
13. Peng RD, Dominici F, Zeger SL. Reproducible epidemiologic research. Am J Epidemiol 2006; 163: 783-789.
14. Murray CJL, Lopez AD, Wang H (eds.). Mortality estimation for national populations: methods and applications. Seattle: University of Washington; 2012.
15. Kuboki M, Shinzawa H, Shao L, Ishibashi M, Yoshii E, Suzuki K, et al. A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-related seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Liver 1999; 19: 88-96.
16. Ishibashi M, Shinzawa H, Kuboki M, Tsuchida H, Takahashi T. Prevalence of inhabitants with anti-hepatitis C virus antibody in an area following an acute hepatitis C epidemic: age-and area-related features. J Epidemiol 1996; 6: 1-7.
17. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa A, et al. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 1995; 90: 794-799.
18. Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. Lower hepatitis G virus infection prevalence compared to hepatitis B and C virus infection prevalences. Diges Dis Sci 2000; 45: 188-195.
19. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
20. Farrugia A, Penrod J, Bult JM. Payment, compensation and replacement-the ethics and motivation of blood and plasma donation. Vox Sang 2010; 99: 202-211.
21. Fernandez-Montoya A. Altruism and payment in blood donation. Transfus Sci 1997; 18: 379-386.
22. Albeldawi M, Ruiz-Rodriguez E, Carey WD. Hepatitis C virus: prevention, screening, and interpretation of assays. Cleve Clin J Med 2010; 77: 616-626.
23. Constantinescu I, Diaconu C, Grancea C, Bleontu C, Ruta SM, Cernescu C. "Trial moves rapidly on, when the judge has determined the sentence beforehand" (W. Scott: Ivanhoe, 36) or pitfalls in serosurvey of anti-hepatitis C antibody in children. Rom J Virol 1998; 49: 11-21.
24. Gelman A. Multilevel (hierarchical) modeling: what it can and cannot do. Technometrics 2006; 48: 432-435.
25. Wakefield J, Shaddick G. Health-exposure modeling and the ecological fallacy. Biostatistics 2006; 7: 438-455.
26. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
27. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. HEPATOLOGY 2000; 31: 777-782.
28. Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health 2007; 31: 30-35.
29. Iversen J, Wand H, Gonnermann A, Maher L. Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. Int J Drug Policy 2010; 21: 471-476.
30. McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Revs 2006: CD005546.
31. Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. HEPATOLOGY 2001; 34: 223-229.
32. Batash S, Khaykis I, Raicht RF, Bini EJ. High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program. Am J Gastroenterol 2008; 103: 922-927.
33. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. HEPATOLOGY 2001; 34: 809-816.
34. Fu B, Tom BD, Delahooke T, Alexander GJ, Bird SM. Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences. J Clin Epidemiol 2007; 60: 1140-1148.
35. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009; 29: 89-99.